Antimicrobial technology company Byotrol plc (AIM: BYOT) announced on Tuesday that it has introduced PROCESSUS, a comprehensive instrument decontamination system, expanding its next-gen surface disinfectant technology.
This launch, the third under Byotrol's ANIGENE and CHEMGENE brands, targets effective reprocessing in both human and animal healthcare settings.
PROCESSUS is to be showcased at the London Vet Show on 16 November 2023, demonstrating ease-of-use and flexibility. The system integrates enzymatic cleaners for organic matter removal before disinfection, featuring a triple enzyme formulation to preserve instrument integrity. Post-cleaning, PROCESSUS Instrument Disinfectant eradicates bacteria, yeasts, fungi, viruses and multi-drug resistant pathogens while denaturing DNA/RNA.
Byotrol's rigorous testing aligns PROCESSUS with the latest European efficacy standards, ensuring compatibility with various equipment, including thermos-sensitive devices and surgical instruments. As an AIM-listed specialist in infection prevention, Byotrol operates globally across animal health, human health, consumer products and facilities management sectors. The company focuses on developing and commercialising innovative biocidal technologies for targeted protection against harmful pathogens.
SHL Telemedicine introduces SmartHeart direct-to-consumer membership plan
Broncus Hangzhou signs Equity Transfer Agreement with Hangzhou Jingliang shareholders
Bracco signs long-term partnership with ulrich GmbH
L&T Technology Services plans to revolutionise medical imaging in collaboration with NVIDIA
Eli Lilly to build new high-tech manufacturing site in Germany
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Zymo Research's SafeCollect Saliva Collection Kit receives US FDA approval
Kanabo Group extends contract with major UK retailer
Biodesix enhances Nodify Lung testing with Tasso+ blood draw method
Byotrol unveils PROCESSUS instrument decontamination system
Integrum plans FDA PMA submission for OPRA in transhumeral amputations
Telix and Mauna Kea Technologies expand collaboration in urologic oncology surgery
Egetis secures exclusive licence agreement with Fujimoto for Emcitate development in Japan
KDx Diagnostics enters into strategic collaborations with leading distributors in Europe